Every Day is Duchenne Awareness Day
By Julz Lowenberg
Patient Advocacy Lead
10/6/25
As we turn the calendar to October, Muscular Dystrophy Awareness Month and World Duchenne Awareness Day (WDAD) have officially come to a close.... Read More
One Year. One Thousand Lives. One Shared Mission.
By Matt Trudeau
President, ITF Therapeutics
9/2/25
One year ago, ITF's first treatment option became available in the U.S. for eligible individuals living with Duchenne muscular dystrophy. In the twelve months since, we’ve reached more than 1,000 families with our therapy – each with their own story, their own fight, their own hope.... Read More
It’s All About the Data
By Mary Jane Salinas, PharmD
Sr. Director, Head of US Scientific Communications and Evidence Generation
6/27/25
My official title is Senior Director, Head of US Scientific Communications and Evidence Generation. It’s a mouthful, I know—and probably not a role most people outside of biotech have heard of.... Read More
ITF in Year Two: Where We Are Headed
By Matt Trudeau
President of ITF Therapeutics
2/26/25
ITF’s first year of operations was unforgettable. We worked at breakneck speed to design and implement all the structures, processes, systems, and procedures necessary to bring a therapy to market. It has been gratifying to introduce a treatment option to a rare disease community that has been yearning, for far too long, for meaningful interventions.... Read More
2024 Wrap Up
By ITF Leadership Team
1/8/25
As we kick off 2025, we wanted to take a moment to reflect on the past year. We all feel a deep sense of gratitude to the Duchenne muscular dystrophy (DMD) community.... Read More
On Building a Mission-Focused Company
By Melinda Keegan
Head of US Human Resources
12/13/24
Launching a new medication in the U.S. is no small feat. It requires a diverse team of specialists such as manufacturing experts, regulatory professionals, field representatives who work with physicians and payers, patient advocates who build bridges to the community, and medical teams... Read More
A Guest in Your Home
By Matt Trudeau
President of ITF Therapeutics
10/31/24
We've all had interactions at one point or another with the kind of house guests who aren't welcome – those who impose themselves on the scene with little regard for their hosts, primarily focused on what they can gain from the situation. I firmly believe that that kind of behavior is also bad in business... Read More
FDA Approval Granted, Access Denied – Now What?
By Stephanie Trafton
Head of US Value & Access
10/3/24
The United States of America is famous for medical innovation. Our country leads the world in the number of new drugs and medical devices that are given the green light by our government. Unfortunately, this does not mean that every approved new... Read More
A Good Day
By Caroline Allen
Head of US Patient Advocacy
7/24/24
In the long path to new treatments for Duchenne, today is a good day. A medicine that is designed to interfere with Duchenne’s relentless progression is now officially available in the United States. While I am feeling positive and hopeful because of this... Read More
